DOWNLOAD
Chamberlain College of Nursing
Antipsychotic Medications Table
Week 3
Course: NR546/NR 546 Advanced
Pharmacology: Psychopharmacology
, THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 3 MEDICATION TABLE
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative metabolism (CYP 450 NT)
effect enzyme)
Potency (if noted. receptor occupancy if noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Indication: (bold for FDA-approved) Decanoate half-life Acute blockade of dopamine 2 receptors in
(Haldol) Manifestations of psychotic disorders (oral, approx. 3 weeks. Oral the striatum can cause drug-induced
P. 361 immediate-release injection). dose half-life approx. Parkinsonism, dystonia, or akathisia.
Tics and vocal utterances in Tourette's syndrome 12-38 hours. Chronic blockade of dopamine 2 receptors in
(oral, immediate-release injections) the striatum can cause tardive dyskinesia.
Second-line treatment of severe behavior Blocking dopamine 2 receptors in the pituitary
problems in children with combative, explosive, can cause elevations in prolactin.
and hyperexcitability (oral). Blocking dopamine 2 receptors excessively in
Second line short-term treatment of hyperactive the mesocortical and mesolimbic dopamine
children (oral). pathways, especially at high doses, can cause
Treatment of schizophrenic patients who require worsening of negative and cognitive
prolonged parenteral antipsychotic therapy (depot symptoms (neuroleptic-induced deficit
intramuscular decanoate). syndrome).
Bipolar disorder. Blocking alpha 1 adrenergic receptors can
Behavioral disturbances and dementias. cause dizziness, hypotension, and syncope.
Delirium (with lorazepam). The mechanism of weight gain and any
possible increased incidence of diabetes or
Blocks dopamine 2 receptors, reducing positive dyslipidemia with conventional antipsychotics
symptoms of psychosis and possibly combative, is unknown.
explosive, and hyperactive behaviors.
Blocks dopamine 2 in the nigrostriatal pathway,
improving tics and other symptoms in Tourette’s.
, Thioridazine Indications: (bold for FDA-approved) Half-life 24 hours Acute blockade of dopamine 2 receptors in
(Mellaril) Schizophrenic patients who fail to respond to (Feinberg, et al., 2023). the striatum can cause drug-induced
P. 791 treatment with other antipsychotic drugs. Metabolized by Parkinsonism, dystonia, or akathisia.
CYP450 2D6 Chronic blockade of dopamine 2 receptors in
Blocks dopamine 2 receptors, reducing positive the striatum can cause tardive dyskinesia.
symptoms of psychosis. Blocking dopamine 2 receptors in the pituitary
can cause elevations in prolactin.
Blocking dopamine 2 receptors excessively in
the mesocortical and mesolimbic dopamine
pathways, especially at high doses, can cause
worsening of negative and cognitive
symptoms (neuroleptic-induced deficit
syndrome).
Blocking muscarinic cholinergic receptors can
cause dry mouth, blurred vision, urinary
retention, constipation, and paralytic ileus.
Antihistaminic actions may cause sedation
and weight gain.
Blocking A1 adrenergic receptors can cause
dizziness, hypotension, and syncope.
The mechanism of weight gain and any
possible increased incidence of diabetes or
dyslipidemia with conventional antipsychotics
is unknown.
The mechanism of potentially dangerous QTC
prolongation may be related to actions at ion
channels.
Thiothixene Indications: (bold for FDA-approved) The initial elimination Acute blockade of dopamine 2 receptors in
(Navane) Schizophrenia. half-life is the striatum can cause drug-induced
P. 797 Other psychotic disorders. approximately 3.4 Parkinsonism, dystonia, or akathisia.
Bipolar disorder. hours. Terminal
Chamberlain College of Nursing
Antipsychotic Medications Table
Week 3
Course: NR546/NR 546 Advanced
Pharmacology: Psychopharmacology
, THIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 3 MEDICATION TABLE
Drug name Indication Half-life (T1/2), Notable side effects (associate to pathway or
Target symptoms: state if positive or negative metabolism (CYP 450 NT)
effect enzyme)
Potency (if noted. receptor occupancy if noted )
Neurotransmitter(s) affected
Typical antipsychotics (conventional)
Haloperidol Indication: (bold for FDA-approved) Decanoate half-life Acute blockade of dopamine 2 receptors in
(Haldol) Manifestations of psychotic disorders (oral, approx. 3 weeks. Oral the striatum can cause drug-induced
P. 361 immediate-release injection). dose half-life approx. Parkinsonism, dystonia, or akathisia.
Tics and vocal utterances in Tourette's syndrome 12-38 hours. Chronic blockade of dopamine 2 receptors in
(oral, immediate-release injections) the striatum can cause tardive dyskinesia.
Second-line treatment of severe behavior Blocking dopamine 2 receptors in the pituitary
problems in children with combative, explosive, can cause elevations in prolactin.
and hyperexcitability (oral). Blocking dopamine 2 receptors excessively in
Second line short-term treatment of hyperactive the mesocortical and mesolimbic dopamine
children (oral). pathways, especially at high doses, can cause
Treatment of schizophrenic patients who require worsening of negative and cognitive
prolonged parenteral antipsychotic therapy (depot symptoms (neuroleptic-induced deficit
intramuscular decanoate). syndrome).
Bipolar disorder. Blocking alpha 1 adrenergic receptors can
Behavioral disturbances and dementias. cause dizziness, hypotension, and syncope.
Delirium (with lorazepam). The mechanism of weight gain and any
possible increased incidence of diabetes or
Blocks dopamine 2 receptors, reducing positive dyslipidemia with conventional antipsychotics
symptoms of psychosis and possibly combative, is unknown.
explosive, and hyperactive behaviors.
Blocks dopamine 2 in the nigrostriatal pathway,
improving tics and other symptoms in Tourette’s.
, Thioridazine Indications: (bold for FDA-approved) Half-life 24 hours Acute blockade of dopamine 2 receptors in
(Mellaril) Schizophrenic patients who fail to respond to (Feinberg, et al., 2023). the striatum can cause drug-induced
P. 791 treatment with other antipsychotic drugs. Metabolized by Parkinsonism, dystonia, or akathisia.
CYP450 2D6 Chronic blockade of dopamine 2 receptors in
Blocks dopamine 2 receptors, reducing positive the striatum can cause tardive dyskinesia.
symptoms of psychosis. Blocking dopamine 2 receptors in the pituitary
can cause elevations in prolactin.
Blocking dopamine 2 receptors excessively in
the mesocortical and mesolimbic dopamine
pathways, especially at high doses, can cause
worsening of negative and cognitive
symptoms (neuroleptic-induced deficit
syndrome).
Blocking muscarinic cholinergic receptors can
cause dry mouth, blurred vision, urinary
retention, constipation, and paralytic ileus.
Antihistaminic actions may cause sedation
and weight gain.
Blocking A1 adrenergic receptors can cause
dizziness, hypotension, and syncope.
The mechanism of weight gain and any
possible increased incidence of diabetes or
dyslipidemia with conventional antipsychotics
is unknown.
The mechanism of potentially dangerous QTC
prolongation may be related to actions at ion
channels.
Thiothixene Indications: (bold for FDA-approved) The initial elimination Acute blockade of dopamine 2 receptors in
(Navane) Schizophrenia. half-life is the striatum can cause drug-induced
P. 797 Other psychotic disorders. approximately 3.4 Parkinsonism, dystonia, or akathisia.
Bipolar disorder. hours. Terminal
